Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

21. Epilepsy in adults. (PubMed)

Epilepsy in adults. Epilepsy is one of the most common serious brain conditions, affecting over 70 million people worldwide. Its incidence has a bimodal distribution with the highest risk in infants and older age groups. Progress in genomic technology is exposing the complex genetic architecture of the common types of epilepsy, and is driving a paradigm shift. Epilepsy is a symptom complex with multiple risk factors and a strong genetic predisposition rather than a condition with a single (...) expression and cause. These advances have resulted in the new classification of epileptic seizures and epilepsies. A detailed clinical history and a reliable eyewitness account of a seizure are the cornerstones of the diagnosis. Ancillary investigations can help to determine cause and prognosis. Advances in brain imaging are helping to identify the structural and functional causes and consequences of the epilepsies. Comorbidities are increasingly recognised as important aetiological and prognostic

2019 Lancet

22. Surgical outcomes for medically intractable epilepsy in low- and middle-income countries: a systematic review and meta-analysis

Surgical outcomes for medically intractable epilepsy in low- and middle-income countries: a systematic review and meta-analysis OBJECTIVEThe aim of this study was to describe the current state of epilepsy surgery and establish estimates of seizure outcomes following surgery for medically intractable epilepsy (MIE) in low- and middle-income countries (LMICs).METHODSThe MEDLINE and Embase databases were searched without publication date restriction. This search was supplemented by a manual screen (...) of key epilepsy and neurosurgical journals (January 2005 to December 2016). Studies that reported outcomes for at least 10 patients of any age undergoing surgery for MIE in LMICs over a defined follow-up period were included. A meta-analysis with a random-effects model was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines. Pooled estimates of seizure

2019 EvidenceUpdates

23. A Prediction Model to Determine Childhood Epilepsy After 1 or More Paroxysmal Events

A Prediction Model to Determine Childhood Epilepsy After 1 or More Paroxysmal Events The clinical profile of children who had possible seizures is heterogeneous, and accuracy of diagnostic testing is limited. We aimed to develop and validate a prediction model that determines the risk of childhood epilepsy by combining available information at first consultation.We retrospectively collected data of 451 children who visited our outpatient department for diagnostic workup related to 1 or more (...) paroxysmal event(s). At least 1 year of follow-up was available for all children who were diagnosed with epilepsy or in whom diagnosis remained inconclusive. Clinical characteristics (sex, age of first seizure, event description, medical history) and EEG report were used as predictor variables for building a multivariate logistic regression model. Performance was validated in an external cohort (n = 187).Model discrimination was excellent, with an area under the receiver operating characteristic curve

2019 EvidenceUpdates

24. Brivaracetam (Briviact) for use in the treatment of patients with refractory epilepsy

Brivaracetam (Briviact) for use in the treatment of patients with refractory epilepsy Brivaracetam (Briviact ® ). Reference number 3387. Page 1 of 3 AWMSG Secretariat Assessment Report – Limited submission Brivaracetam (Briviact ® ? ) 10 mg, 25 mg, 50 mg, 75 mg and 100 mg film-coated tablets; 10 mg/ml oral solution; 10 mg/ml solution for injection/infusion Company: UCB Pharma Ltd Licensed indication under consideration: As adjunctive therapy in the treatment of partial onset seizures (...) with or without secondary generalisation in children from 4 to = 15 years of age with epilepsy. Brivaracetam (Briviact ® ) should be restricted to use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines. ? This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Date

2019 All Wales Medicines Strategy Group

25. The prevalence of comorbidity in epilepsy: a systematic review and meta-analysis

The prevalence of comorbidity in epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

26. The interface between temporal lobe epilepsy and symptoms of depression: a systematic review

The interface between temporal lobe epilepsy and symptoms of depression: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

27. Feasibility of quality-of-life patient-reported outcome measurement in epilepsy clinics: a systematic review

Feasibility of quality-of-life patient-reported outcome measurement in epilepsy clinics: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

28. Interventions that influence outcomes of epilepsy in mitochondrial disease: a systematic review

Interventions that influence outcomes of epilepsy in mitochondrial disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

29. Association between Helicobacter pylori infection and epilepsy : a systematic review and meta-analysis

Association between Helicobacter pylori infection and epilepsy : a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

30. Anti-epileptic medication non-adherence and associated factors among adults with epilepsy treatment in Ethiopia: a systematic review and meta analysis

Anti-epileptic medication non-adherence and associated factors among adults with epilepsy treatment in Ethiopia: a systematic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

31. Antiepileptic drugs for the management of epilepsy in children under 5 years with tuberous sclerosis complex [Cochrane protocol]

Antiepileptic drugs for the management of epilepsy in children under 5 years with tuberous sclerosis complex [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

32. Current prevalences and their proportions of anxiety disorders in epilepsy clinics for routine care: a meta-analysis

Current prevalences and their proportions of anxiety disorders in epilepsy clinics for routine care: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

33. Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy [Cochrane protocol]

Stimulant and non-stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

34. Assessing the effectiveness of magnetic resonance guided laser interstitial thermal therapy among patients with medically intractable epilepsy: a systematic review and meta-analysis

Assessing the effectiveness of magnetic resonance guided laser interstitial thermal therapy among patients with medically intractable epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

35. Math and numeracy skills in epilepsy: a systematic review and meta-analysis

Math and numeracy skills in epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

36. Effect of the ketogenic diet on cognition and markers and neuroplasticity in refractory epilepsy: a systematic review

Effect of the ketogenic diet on cognition and markers and neuroplasticity in refractory epilepsy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

37. Vitamin E as add-on therapy for epilepsy: a systematic review and meta-analysis

Vitamin E as add-on therapy for epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

38. Treatments for peri-menstrual seizures in catamenial epilepsy [Cochrane protocol]

Treatments for peri-menstrual seizures in catamenial epilepsy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

39. Effectiveness of AEDs for childhood epilepsy with centrotemporal spikes (CECTS)

Effectiveness of AEDs for childhood epilepsy with centrotemporal spikes (CECTS) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

40. What is the effectiveness of genetic testing in determining the aetiology of epilepsy?

What is the effectiveness of genetic testing in determining the aetiology of epilepsy? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO